Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132678 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
NCT00132678 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 559 participants.
The verdict
NCT00132678, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.
Interventions
- DRUG Placebo
- DRUG Risperdal Consta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132678
The ClinicalTrials.gov registry entry for NCT00132678 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00132678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132678 about?
NCT00132678 is a clinical study titled "A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes". The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.
What is the current status of trial NCT00132678?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2005-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00132678?
The interventions under investigation include: Placebo (DRUG), Risperdal Consta (DRUG).
Who is sponsoring clinical trial NCT00132678?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.